Aclaris Therapeutics to release clinical trial results April 28

Aclaris Therapeutics, Inc. (NASDAQ: ACRS) announced it will release results from its Phase 1a trial of anti-TSLP/IL-4R bispecific antibody ATI-052 and lead indication selection results for ITK/JAK3 inhibitor ATI-2138 on April 28, 2026, before market opening.

The Wayne, Pennsylvania-based clinical-stage biopharmaceutical company will host a webcast and conference call at 8:30 AM EST on April 28 to discuss the updates. The Phase 1a trial examined single and multiple ascending doses of ATI-052.

Aclaris focuses on developing treatments for immuno-inflammatory diseases. The company stated the webcast will be archived on its website for 30 days following the event.

You May Also Be Interested In

• Fervo Energy, Nvidia, and PNNL to build geothermal digital twin
• WeRide partners with Geely Farizon and Kwoon Chung on right-hand-drive robotaxi
• SpaceX (SPCX) call put ratio 1 call to 1 put on 1.9M contracts